Scientific Reports,
Год журнала:
2024,
Номер
14(1)
Опубликована: Дек. 28, 2024
The
prevalence
of
Alzheimer's
disease
(AD)
is
on
the
rise
globally,
and
everyone
who
develops
AD
eventually
experiences
mild
cognitive
impairment
(MCI)
first.
Timely
intervention
at
an
early
stage
may
mitigate
progression.
Recent
studies
indicate
that
BDNF
MMP-9
play
a
significant
role
in
pathogenesis
AD.
Therefore,
this
study
aims
to
ascertain
whether
there
are
differences
plasma
levels
between
individuals
with
due
those
normal
cognition,
analyze
factors
influencing
impairment.This
case-control
included
102
controls,
matched
by
age
sex.
Participants
completed
series
questionnaires,
neuropsychological
assessments,
clinical
examinations.
Plasma
concentrations
participants
were
quantified
using
ELISA.
Subsequently,
MCI
analyzed
univariate
multivariate
logistic
regression.
levels,
MOCA
total
scores,
scores
various
domains
(including
visuospatial
executive
abilities,
abstract
thinking,
attention,
language,
naming,
delayed
memory)
control
groups
showed
statistically
(p
<
0.05).
Logistic
regression
analysis
revealed
years
formal
education
significantly
negatively
associated
MCI.
This
indicates
protective
function.
Alzheimer s & Dementia,
Год журнала:
2024,
Номер
20(9), С. 6506 - 6516
Опубликована: Июль 19, 2024
Abstract
INTRODUCTION
We
aimed
to
evaluate
clinical
interpretation
cutpoints
for
two
plasma
phosphorylated
tau
(p‐tau)217
assays
(ALZpath
and
Lumipulse)
as
predictors
of
amyloid
status
implementation
in
practice.
METHODS
Clinical
performance
p‐tau217
against
positron
emission
tomography
was
evaluated
participants
with
mild
cognitive
impairment
or
dementia
(
n
=
427).
RESULTS
Using
a
one‐cutpoint
approach
(negative/positive),
neither
assay
achieved
≥
90%
both
sensitivity
specificity.
A
two‐cutpoint
yielding
92%
96%
specificity
provided
the
desired
balance
false
positives
negatives,
while
categorizing
20%
39%
results
indeterminate
Lumipulse
ALZpath
assays,
respectively.
DISCUSSION
This
study
provides
systematic
framework
selection
assay‐specific
use
determination
status.
Our
findings
suggest
that
may
have
advantages
optimizing
diagnostic
accuracy
minimizing
potential
harm
from
positive
results.
Highlights
Phosphorylated
detection
pathology
were
established.
exhibited
best
laboratory
use.
differed
percentage
categorized
intermediate.
Nature Communications,
Год журнала:
2024,
Номер
15(1)
Опубликована: Июль 5, 2024
Abstract
A
major
challenge
in
Parkinson’s
disease
is
the
variability
symptoms
and
rates
of
progression,
underpinned
by
heterogeneity
pathological
processes.
Biomarkers
are
urgently
needed
for
accurate
diagnosis,
patient
stratification,
monitoring
progression
precise
treatment.
These
were
previously
lacking,
but
recently,
novel
imaging
fluid
biomarkers
have
been
developed.
Here,
we
consider
new
approaches
showing
sensitivity
to
brain
tissue
composition,
examine
specificity
processes,
including
seed
amplification
assays
extracellular
vesicles.
We
reflect
on
these
context
biological
staging
systems,
emerging
techniques
currently
development.
Biosensors,
Год журнала:
2025,
Номер
15(2), С. 85 - 85
Опубликована: Фев. 4, 2025
Alzheimer’s
disease
(AD)
is
a
prevalent
neurodegenerative
disorder
and
significant
cause
of
dementia
in
elderly
individuals,
with
growing
prevalence
our
aging
population.
Extracellular
amyloid-β
peptides
(Aβ),
intracellular
tau
proteins,
their
phosphorylated
forms
have
gained
prominence
as
critical
biomarkers
for
early
precise
diagnosis
AD,
correlating
progression
response
to
therapy.
The
high
costs
invasiveness
conventional
diagnostic
methods,
such
positron
emission
tomography
(PET)
magnetic
resonance
imaging
(MRI),
limit
suitability
large-scale
or
routine
screening.
However,
electrochemical
(EC)
analysis
methods
made
progress
detection
due
sensitivity,
excellent
specificity,
portability,
cost-effectiveness.
This
article
reviews
the
EC
biosensing
technologies,
focusing
on
protein
blood
(a
low-invasive,
accessible
medium).
then
discusses
various
sensing
platforms,
including
fabrication
processes,
(LOD),
clinical
potential
show
role
these
sensors
transformers
changing
face
AD
diagnostics.
medRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 22, 2024
BACKGROUND:
Phosphorylated
tau
(p-tau)
is
a
specific
blood
biomarker
for
Alzheimers
disease
(AD)
pathology.
Multiple
p-tau
biomarkers
on
several
analytical
platforms
are
poised
clinical
use.
The
Association
Global
Biomarker
Standardisation
Consortium
plasma
phospho-tau
Round
Robin
study
engaged
assay
developers
in
blinded
case-control
p-tau,
aiming
to
learn
which
assays
provide
the
largest
fold-changes
AD
compared
non-AD,
have
strongest
relationship
between
and
cerebrospinal
fluid
(CSF),
show
most
consistent
relationships
methods
(commutability)
measuring
both
patient
samples
candidate
reference
materials
(CRM).
METHODS:
Thirty-three
different
assays,
built
eight
platforms,
were
used
quantify
paired
CSF
from
40
participants.
status
was
categorised
as
pathology
(n=25)
non-AD
(n=15)
by
Aβ42/Aβ40
(US-FDA;
CE-IVDR)
p-tau181
(CE-IVDR)
methods.
commutability
of
four
CRM,
at
three
concentrations,
assessed
across
assays.
FINDINGS:
Plasma
p-tau217
consistently
demonstrated
higher
groups,
other
epitopes.
Fujirebio
LUMIPULSE
G,
UGOT
IPMS,
Lilly
MSD
provided
highest
median
fold-changes.
In
CSF,
also
performed
best,
exhibited
substantially
larger
than
their
counterparts,
despite
similar
diagnostic
performance.
P-tau217
showed
correlations
(rho=0.81
0.97).
levels
weakly-to-moderately
correlated
with
non-significant
within
group
alone.
evaluated
CRM
not
commutable
INTERPRETATION:
measures
had
discriminative
accuracies
detecting
pathology,
better
agreement
variants.
markers
measured
immunoassays,
correlated,
questioning
interchangeability
continuous
relationship.
Further
work
warranted
understand
pathophysiology
underlying
this
dissociation,
develop
suitable
facilitating
cross-assay
standardisation.
FUNDING:
(#ADSF-24-1284328-C)
Alzheimer s & Dementia,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 5, 2025
The
Alzheimer's
Association
Global
Biomarker
Standardization
Consortium
conducted
a
blinded
case-control
study
to
learn
which
phosphorylated
tau
(p-tau)
assays
provide
the
largest
fold-changes
in
disease
(AD)
versus
non-AD
and
show
commutability
measuring
patient
samples
candidate
certified
reference
materials
(CRMs).
Thirty-three
different
p-tau
measured
paired
plasma
cerebrospinal
fluid
(CSF)
from
40
participants
(25
with
"AD
pathology"
15
"non-AD
by
CSF
amyloid
beta
[Aβ]42/Aβ40
p-tau181
criteria).
Four
CRMs
were
assessed.
Plasma
p-tau217
demonstrated
higher
between
AD
than
other
epitopes.
Fujirebio
LUMIPULSE
G,
UGOT
IPMS,
Lilly
MSD
provided
highest
fold-changes.
showed
strongest
correlations
(rho
=
0.81-0.97).
not
commutable
across
assays.
larger
better
accuracy
for
detecting
pathology
symptomatic
individuals,
greater
cross-platform
agreement
variants.
Further
work
is
needed
develop
suitable
facilitating
cross-assay
standardization.
Paired
twenty-five
patients
blind.
compared,
tau-181
(p-tau181),
205,
212,
217
231.
consistently
had
fold-change
was
best
correlated
Plasma-CSF
weak
moderate.
There
lack
of
four
materials.
